Table 2.

Disproportionality analysis of GLP-1RAs-associated depressive disorders versus reference non-GLP-1RA drugs in the FAERS database.

Drug 1 (case)		Drug 2 (non-case)		ROR	95% CI	IC	95% CI
Liraglutide	224	Orlistat	116	1.38	1.11–1.73	0.17	−0.075 to 0.42
Liraglutide	224	Metformin	368	1.94	1.64–2.29	0.66	0.43–0.88
Liraglutide	224	Empagliflozin	67	2.88	2.19–3.78	0.51	0.25–0.77
Semaglutide	542	Orlistat	116	2.32	1.90–2.83	0.30	0.13–0.46
Semaglutide	542	Metformin	368	3.25	2.85–3.71	0.93	0.77–1.08
Semaglutide	542	Empagliflozin	67	4.82	3.74–6.22	0.50	0.33–0.67
Tirzepatide	227	Orlistat	116	0.90	0.72–1.13	−0.052	−0.30 to 0.19
Tirzepatide	227	Metformin	368	1.06	1.07–1.49	0.22	−0.087 to 0.44
Tirzepatide	227	Empagliflozin	67	1.58	1.19–2.10	0.26	−0.024 to 0.51

Note: ROR, reporting odds ratio; CI, confidence interval; IC, Bayesian information component.